Head and neck cancer has a poor prognosis despite aggressive treatments. Novel immunotherapies are effective in only a minority of patients, therefore new combination treatments with immunotherapies are needed. We will treat patients with a taxane chemotherapy prior to surgery to study the potential favorable changes within the tumor and immune system response.